The impact of transcranial magnetic stimulation on diagnostic confidence in patients with Alzheimer disease

Cholinergic dysfunction is a key abnormality in Alzheimer disease (AD) that can be detected in vivo with transcranial magnetic stimulation (TMS) protocols. Although TMS has clearly demonstrated analytical validity, its clinical utility is still debated. In the present study, we evaluated the increme...

Full description

Saved in:
Bibliographic Details
Published inAlzheimer's research & therapy Vol. 10; no. 1; p. 94
Main Authors Benussi, Alberto, Alberici, Antonella, Ferrari, Clarissa, Cantoni, Valentina, Dell'Era, Valentina, Turrone, Rosanna, Cotelli, Maria Sofia, Binetti, Giuliano, Paghera, Barbara, Koch, Giacomo, Padovani, Alessandro, Borroni, Barbara
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 18.09.2018
BioMed Central
BMC
Subjects
Accuracy
Alzheimer disease
Alzheimer's disease
Biomarkers
Brain research
Confidence
Dementia
Diagnosis
Frontotemporal dementia
Magnetic brain stimulation
Medical diagnosis
PET amyloid
Transcranial magnetic stimulation
Transcranial magnetic stimulation
Diagnosis
Frontotemporal dementia
Alzheimer disease
Confidence
PET amyloid
Online AccessGet full text

Cover

Abstract Cholinergic dysfunction is a key abnormality in Alzheimer disease (AD) that can be detected in vivo with transcranial magnetic stimulation (TMS) protocols. Although TMS has clearly demonstrated analytical validity, its clinical utility is still debated. In the present study, we evaluated the incremental diagnostic value, expressed in terms of diagnostic confidence of Alzheimer disease (DCAD; range 0-100), of TMS measures in addition to the routine clinical diagnostic assessment in patients evaluated for cognitive impairment as compared with validated biomarkers of amyloidosis. One hundred twenty patients with dementia were included and scored in terms of DCAD in a three-step assessment based on (1) demographic, clinical, and neuropsychological evaluations (clinical work-up); (2) clinical work-up plus amyloid markers (cerebrospinal fluid or amyloid positron emission tomographic imaging); and (3) clinical work-up plus TMS intracortical connectivity measures. Two blinded neurologists were asked to review the diagnosis and diagnostic confidence at each step. TMS measures increased the discrimination of DCAD in two clusters (AD-like vs FTD-like) when added to the clinical and neuropsychological evaluations with levels comparable to established biomarkers of brain amyloidosis (cluster distance of 55.1 for clinical work-up alone, 76.0 for clinical work-up plus amyloid markers, 80.0 for clinical work-up plus TMS). Classification accuracy for the "gold standard" diagnosis (dichotomous - AD vs FTD - variable) evaluated in the three-step assessment, expressed as AUC, increased from 0.82 (clinical work-up alone) to 0.98 (clinical work-up plus TMS) and to 0.99 (clinical work-up plus amyloidosis markers). TMS in addition to routine assessment in patients with dementia has a significant effect on diagnosis and diagnostic confidence that is comparable to well-established amyloidosis biomarkers.
AbstractList Background Cholinergic dysfunction is a key abnormality in Alzheimer disease (AD) that can be detected in vivo with transcranial magnetic stimulation (TMS) protocols. Although TMS has clearly demonstrated analytical validity, its clinical utility is still debated. In the present study, we evaluated the incremental diagnostic value, expressed in terms of diagnostic confidence of Alzheimer disease (DCAD; range 0-100), of TMS measures in addition to the routine clinical diagnostic assessment in patients evaluated for cognitive impairment as compared with validated biomarkers of amyloidosis. Methods One hundred twenty patients with dementia were included and scored in terms of DCAD in a three-step assessment based on (1) demographic, clinical, and neuropsychological evaluations (clinical work-up); (2) clinical work-up plus amyloid markers (cerebrospinal fluid or amyloid positron emission tomographic imaging); and (3) clinical work-up plus TMS intracortical connectivity measures. Two blinded neurologists were asked to review the diagnosis and diagnostic confidence at each step. Results TMS measures increased the discrimination of DCAD in two clusters (AD-like vs FTD-like) when added to the clinical and neuropsychological evaluations with levels comparable to established biomarkers of brain amyloidosis (cluster distance of 55.1 for clinical work-up alone, 76.0 for clinical work-up plus amyloid markers, 80.0 for clinical work-up plus TMS). Classification accuracy for the "gold standard" diagnosis (dichotomous - AD vs FTD - variable) evaluated in the three-step assessment, expressed as AUC, increased from 0.82 (clinical work-up alone) to 0.98 (clinical work-up plus TMS) and to 0.99 (clinical work-up plus amyloidosis markers). Conclusions TMS in addition to routine assessment in patients with dementia has a significant effect on diagnosis and diagnostic confidence that is comparable to well-established amyloidosis biomarkers. Keywords: Alzheimer disease, Frontotemporal dementia, Transcranial magnetic stimulation, PET amyloid, Diagnosis, Confidence
Background Cholinergic dysfunction is a key abnormality in Alzheimer disease (AD) that can be detected in vivo with transcranial magnetic stimulation (TMS) protocols. Although TMS has clearly demonstrated analytical validity, its clinical utility is still debated. In the present study, we evaluated the incremental diagnostic value, expressed in terms of diagnostic confidence of Alzheimer disease (DCAD; range 0–100), of TMS measures in addition to the routine clinical diagnostic assessment in patients evaluated for cognitive impairment as compared with validated biomarkers of amyloidosis. Methods One hundred twenty patients with dementia were included and scored in terms of DCAD in a three-step assessment based on (1) demographic, clinical, and neuropsychological evaluations (clinical work-up); (2) clinical work-up plus amyloid markers (cerebrospinal fluid or amyloid positron emission tomographic imaging); and (3) clinical work-up plus TMS intracortical connectivity measures. Two blinded neurologists were asked to review the diagnosis and diagnostic confidence at each step. Results TMS measures increased the discrimination of DCAD in two clusters (AD-like vs FTD-like) when added to the clinical and neuropsychological evaluations with levels comparable to established biomarkers of brain amyloidosis (cluster distance of 55.1 for clinical work-up alone, 76.0 for clinical work-up plus amyloid markers, 80.0 for clinical work-up plus TMS). Classification accuracy for the “gold standard” diagnosis (dichotomous - AD vs FTD - variable) evaluated in the three-step assessment, expressed as AUC, increased from 0.82 (clinical work-up alone) to 0.98 (clinical work-up plus TMS) and to 0.99 (clinical work-up plus amyloidosis markers). Conclusions TMS in addition to routine assessment in patients with dementia has a significant effect on diagnosis and diagnostic confidence that is comparable to well-established amyloidosis biomarkers.
Cholinergic dysfunction is a key abnormality in Alzheimer disease (AD) that can be detected in vivo with transcranial magnetic stimulation (TMS) protocols. Although TMS has clearly demonstrated analytical validity, its clinical utility is still debated. In the present study, we evaluated the incremental diagnostic value, expressed in terms of diagnostic confidence of Alzheimer disease (DCAD; range 0-100), of TMS measures in addition to the routine clinical diagnostic assessment in patients evaluated for cognitive impairment as compared with validated biomarkers of amyloidosis. One hundred twenty patients with dementia were included and scored in terms of DCAD in a three-step assessment based on (1) demographic, clinical, and neuropsychological evaluations (clinical work-up); (2) clinical work-up plus amyloid markers (cerebrospinal fluid or amyloid positron emission tomographic imaging); and (3) clinical work-up plus TMS intracortical connectivity measures. Two blinded neurologists were asked to review the diagnosis and diagnostic confidence at each step. TMS measures increased the discrimination of DCAD in two clusters (AD-like vs FTD-like) when added to the clinical and neuropsychological evaluations with levels comparable to established biomarkers of brain amyloidosis (cluster distance of 55.1 for clinical work-up alone, 76.0 for clinical work-up plus amyloid markers, 80.0 for clinical work-up plus TMS). Classification accuracy for the "gold standard" diagnosis (dichotomous - AD vs FTD - variable) evaluated in the three-step assessment, expressed as AUC, increased from 0.82 (clinical work-up alone) to 0.98 (clinical work-up plus TMS) and to 0.99 (clinical work-up plus amyloidosis markers). TMS in addition to routine assessment in patients with dementia has a significant effect on diagnosis and diagnostic confidence that is comparable to well-established amyloidosis biomarkers.
Abstract Background Cholinergic dysfunction is a key abnormality in Alzheimer disease (AD) that can be detected in vivo with transcranial magnetic stimulation (TMS) protocols. Although TMS has clearly demonstrated analytical validity, its clinical utility is still debated. In the present study, we evaluated the incremental diagnostic value, expressed in terms of diagnostic confidence of Alzheimer disease (DCAD; range 0–100), of TMS measures in addition to the routine clinical diagnostic assessment in patients evaluated for cognitive impairment as compared with validated biomarkers of amyloidosis. Methods One hundred twenty patients with dementia were included and scored in terms of DCAD in a three-step assessment based on (1) demographic, clinical, and neuropsychological evaluations (clinical work-up); (2) clinical work-up plus amyloid markers (cerebrospinal fluid or amyloid positron emission tomographic imaging); and (3) clinical work-up plus TMS intracortical connectivity measures. Two blinded neurologists were asked to review the diagnosis and diagnostic confidence at each step. Results TMS measures increased the discrimination of DCAD in two clusters (AD-like vs FTD-like) when added to the clinical and neuropsychological evaluations with levels comparable to established biomarkers of brain amyloidosis (cluster distance of 55.1 for clinical work-up alone, 76.0 for clinical work-up plus amyloid markers, 80.0 for clinical work-up plus TMS). Classification accuracy for the “gold standard” diagnosis (dichotomous - AD vs FTD - variable) evaluated in the three-step assessment, expressed as AUC, increased from 0.82 (clinical work-up alone) to 0.98 (clinical work-up plus TMS) and to 0.99 (clinical work-up plus amyloidosis markers). Conclusions TMS in addition to routine assessment in patients with dementia has a significant effect on diagnosis and diagnostic confidence that is comparable to well-established amyloidosis biomarkers.
BACKGROUNDCholinergic dysfunction is a key abnormality in Alzheimer disease (AD) that can be detected in vivo with transcranial magnetic stimulation (TMS) protocols. Although TMS has clearly demonstrated analytical validity, its clinical utility is still debated. In the present study, we evaluated the incremental diagnostic value, expressed in terms of diagnostic confidence of Alzheimer disease (DCAD; range 0-100), of TMS measures in addition to the routine clinical diagnostic assessment in patients evaluated for cognitive impairment as compared with validated biomarkers of amyloidosis. METHODSOne hundred twenty patients with dementia were included and scored in terms of DCAD in a three-step assessment based on (1) demographic, clinical, and neuropsychological evaluations (clinical work-up); (2) clinical work-up plus amyloid markers (cerebrospinal fluid or amyloid positron emission tomographic imaging); and (3) clinical work-up plus TMS intracortical connectivity measures. Two blinded neurologists were asked to review the diagnosis and diagnostic confidence at each step. RESULTSTMS measures increased the discrimination of DCAD in two clusters (AD-like vs FTD-like) when added to the clinical and neuropsychological evaluations with levels comparable to established biomarkers of brain amyloidosis (cluster distance of 55.1 for clinical work-up alone, 76.0 for clinical work-up plus amyloid markers, 80.0 for clinical work-up plus TMS). Classification accuracy for the "gold standard" diagnosis (dichotomous - AD vs FTD - variable) evaluated in the three-step assessment, expressed as AUC, increased from 0.82 (clinical work-up alone) to 0.98 (clinical work-up plus TMS) and to 0.99 (clinical work-up plus amyloidosis markers). CONCLUSIONSTMS in addition to routine assessment in patients with dementia has a significant effect on diagnosis and diagnostic confidence that is comparable to well-established amyloidosis biomarkers.
Cholinergic dysfunction is a key abnormality in Alzheimer disease (AD) that can be detected in vivo with transcranial magnetic stimulation (TMS) protocols. Although TMS has clearly demonstrated analytical validity, its clinical utility is still debated. In the present study, we evaluated the incremental diagnostic value, expressed in terms of diagnostic confidence of Alzheimer disease (DCAD; range 0-100), of TMS measures in addition to the routine clinical diagnostic assessment in patients evaluated for cognitive impairment as compared with validated biomarkers of amyloidosis. One hundred twenty patients with dementia were included and scored in terms of DCAD in a three-step assessment based on (1) demographic, clinical, and neuropsychological evaluations (clinical work-up); (2) clinical work-up plus amyloid markers (cerebrospinal fluid or amyloid positron emission tomographic imaging); and (3) clinical work-up plus TMS intracortical connectivity measures. Two blinded neurologists were asked to review the diagnosis and diagnostic confidence at each step. TMS measures increased the discrimination of DCAD in two clusters (AD-like vs FTD-like) when added to the clinical and neuropsychological evaluations with levels comparable to established biomarkers of brain amyloidosis (cluster distance of 55.1 for clinical work-up alone, 76.0 for clinical work-up plus amyloid markers, 80.0 for clinical work-up plus TMS). Classification accuracy for the "gold standard" diagnosis (dichotomous - AD vs FTD - variable) evaluated in the three-step assessment, expressed as AUC, increased from 0.82 (clinical work-up alone) to 0.98 (clinical work-up plus TMS) and to 0.99 (clinical work-up plus amyloidosis markers). TMS in addition to routine assessment in patients with dementia has a significant effect on diagnosis and diagnostic confidence that is comparable to well-established amyloidosis biomarkers.
ArticleNumber 94
Audience Academic
Author Paghera, Barbara
Borroni, Barbara
Koch, Giacomo
Turrone, Rosanna
Binetti, Giuliano
Cantoni, Valentina
Dell'Era, Valentina
Alberici, Antonella
Benussi, Alberto
Padovani, Alessandro
Ferrari, Clarissa
Cotelli, Maria Sofia
Author_xml – sequence: 1
  givenname: Alberto
  surname: Benussi
  fullname: Benussi, Alberto
  organization: Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
– sequence: 2
  givenname: Antonella
  surname: Alberici
  fullname: Alberici, Antonella
  organization: Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
– sequence: 3
  givenname: Clarissa
  surname: Ferrari
  fullname: Ferrari, Clarissa
  organization: IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
– sequence: 4
  givenname: Valentina
  surname: Cantoni
  fullname: Cantoni, Valentina
  organization: Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy
– sequence: 5
  givenname: Valentina
  surname: Dell'Era
  fullname: Dell'Era, Valentina
  organization: Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
– sequence: 6
  givenname: Rosanna
  surname: Turrone
  fullname: Turrone, Rosanna
  organization: Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
– sequence: 7
  givenname: Maria Sofia
  surname: Cotelli
  fullname: Cotelli, Maria Sofia
  organization: Neurology Unit, Ospedale Vallecamonica, Esine, Brescia, Italy
– sequence: 8
  givenname: Giuliano
  surname: Binetti
  fullname: Binetti, Giuliano
  organization: IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
– sequence: 9
  givenname: Barbara
  surname: Paghera
  fullname: Paghera, Barbara
  organization: Nuclear Medicine Unit, Spedali Civili Brescia, Brescia, Italy
– sequence: 10
  givenname: Giacomo
  surname: Koch
  fullname: Koch, Giacomo
  organization: Stroke Unit, Policlinico Tor Vergata, Rome, Italy
– sequence: 11
  givenname: Alessandro
  surname: Padovani
  fullname: Padovani, Alessandro
  organization: Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
– sequence: 12
  givenname: Barbara
  orcidid: 0000-0001-9340-9814
  surname: Borroni
  fullname: Borroni, Barbara
  email: bborroni@inwind.it
  organization: Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy. bborroni@inwind.it
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30227895$$D View this record in MEDLINE/PubMed
BookMark eNptkl2L1DAUhousuB_6A7yRgiDedG3SJE1vhGFZdWHBm_U65ONkmrFNxqZd0V-_Z5x1mRFpaUrO875tznnPi5OYIhTFa1JfEiLFh0wa0vGqJrKqGW0q8aw4Iy2XVUe65uTg_bQ4z3lT10JQyV4Up01NaSs7flZ8v-uhDONW27lMvpwnHbPFR9BDOep1hDnYMs9hXAY9hxRLvF3AQsq7ik3RBwfRokkst4hAnHP5M8x9uRp-9xBGmFCQQWd4WTz3esjw6nG9KL59ur67-lLdfv18c7W6rSzvyFzRVghuGm2obm3HvbO6aZ0XNTCpmQDqammY45Q5B54C8Q6E4YaallgC0FwUN3tfl_RGbacw6umXSjqoPxtpWis94d8PoLhhwkgmqdOMccu18Y5oT4wkzjtD0evj3mu7mBGcxeNNejgyPa7E0Kt1uleCMI7DQYP3jwZT-rFAntUYsoVh0BHSkhUlhJJOUCIRffsPuknLFLFVSNVdLRsqD6i1xgOE6BN-1-5M1YrztqU45A6py_9QeDkYA04NfMD9I8G7A0EPepj7nIZlN_R8DJI9aKeU8wT-qRmkVrtYqn0sFcZS7WKpBGreHHbxSfE3h80DqzLgvg
CitedBy_id crossref_primary_10_1080_14737175_2023_2228491
crossref_primary_10_1186_s40035_020_00224_z
crossref_primary_10_1007_s12264_021_00781_x
crossref_primary_10_2147_JEP_S262352
crossref_primary_10_3233_JAD_190986
crossref_primary_10_1016_j_brs_2021_03_007
crossref_primary_10_1002_jmd2_12059
crossref_primary_10_3389_fnins_2019_00304
crossref_primary_10_1016_j_clinph_2023_03_010
crossref_primary_10_3389_fnagi_2021_737281
crossref_primary_10_3233_JAD_200608
crossref_primary_10_3389_fnhum_2020_00153
crossref_primary_10_3389_fnins_2019_00658
crossref_primary_10_1016_j_arr_2022_101660
crossref_primary_10_1080_14737175_2022_2170784
crossref_primary_10_3389_fncel_2019_00584
crossref_primary_10_3390_brainsci13091332
crossref_primary_10_1186_s13195_019_0555_3
crossref_primary_10_1016_j_jns_2023_120777
crossref_primary_10_1016_j_neubiorev_2023_105451
crossref_primary_10_1016_j_brs_2021_01_004
crossref_primary_10_1186_s13195_022_01094_5
crossref_primary_10_1016_j_clinph_2021_05_035
crossref_primary_10_1007_s11065_023_09589_0
crossref_primary_10_1016_j_biopsych_2023_07_012
crossref_primary_10_3390_jcm10132875
crossref_primary_10_1002_mds_27736
crossref_primary_10_3389_fneur_2020_584664
crossref_primary_10_1002_trc2_12033
crossref_primary_10_1016_j_pnpbp_2024_110967
crossref_primary_10_3390_brainsci11030405
crossref_primary_10_1016_j_brs_2019_11_009
crossref_primary_10_1016_j_procs_2020_02_230
crossref_primary_10_1016_j_seizure_2024_07_001
Cites_doi 10.1002/hbm.21111
10.1212/WNL.59.3.392
10.1007/BF01997792
10.3109/21678421.2014.971812
10.1016/S1474-4422(12)70142-4
10.1212/WNL.0b013e31823b9c5e
10.1111/j.2517-6161.1977.tb01600.x
10.1001/jama.1963.03060120024016
10.1113/jphysiol.1993.sp019912
10.1016/j.jalz.2012.11.007
10.1016/S1474-4422(14)70090-0
10.3233/JAD-170584
10.1016/S1474-4422(15)00153-2
10.1002/ana.24731
10.1093/brain/awr179
10.1016/j.clinph.2015.02.001
10.1038/nrneurol.2017.96
10.1016/0304-3940(87)90016-4
10.1093/geront/9.3_Part_1.179
10.1016/j.jalz.2011.03.005
10.1007/s00401-011-0884-1
10.1016/S1474-4422(09)70139-5
10.1007/s00401-012-1006-4
10.1093/brain/awx327
10.1212/WNL.43.11.2412-a
10.1001/jamaneurol.2016.3751
10.1001/jamapsychiatry.2017.3292
10.1136/jnnp.2010.207183
10.2174/092986707780598005
10.1212/WNL.0000000000004232
10.1111/j.1468-1331.1996.tb00423.x
10.1016/j.dadm.2017.05.005
10.1159/000051219
10.1007/s00265-010-1029-6
10.1016/S1474-4422(17)30159-X
10.1038/nn.2583
10.1186/2051-5960-1-34
10.1136/jnnp-2013-306948
10.1002/ana.21610
10.1093/brain/awx254
10.1111/j.1469-7793.2000.t01-1-00503.x
10.1007/8904_2016_33
10.1016/j.neuroimage.2017.12.048
10.1007/s00221-006-0365-2
10.1212/WNL.44.12.2308
10.1002/ana.24695
10.1016/j.brs.2017.11.013
10.1212/WNL.0b013e31821103e6
10.1007/s100720200003
10.3233/JAD-2012-120532
10.3389/fnagi.2013.00006
10.1016/j.tig.2005.09.005
10.1136/jnnp.66.2.137
10.1113/jphysiol.1996.sp021734
10.1038/npp.2013.154
10.3233/JAD-180293
10.18637/jss.v018.i06
10.1093/brain/awn016
10.1016/j.biopsych.2007.02.027
ContentType Journal Article
Copyright COPYRIGHT 2018 BioMed Central Ltd.
Copyright © 2018. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s). 2018
Copyright_xml – notice: COPYRIGHT 2018 BioMed Central Ltd.
– notice: Copyright © 2018. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s). 2018
DBID NPM
AAYXX
CITATION
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
M1P
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s13195-018-0423-6
DatabaseName PubMed
CrossRef
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
Medical Database
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle PubMed
CrossRef
Publicly Available Content Database
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest Medical Library
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest One Academic
ProQuest Medical Library (Alumni)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
Publicly Available Content Database

PubMed

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: 7X7
  name: Health & Medical Collection
  url: https://search.proquest.com/healthcomplete
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
EISSN 1758-9193
EndPage 94
ExternalDocumentID oai_doaj_org_article_5b46b8482da445c5abfd1af1b81dfdb2
A557726629
10_1186_s13195_018_0423_6
30227895
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
-56
-5G
-BR
0R~
23M
2WC
3V.
53G
5VS
6J9
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
ABDBF
ABUWG
ACGFS
ACIHN
ACJQM
ACRMQ
ADBBV
ADINQ
ADUKV
AEAQA
AFGXO
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIAM
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C24
C6C
CCPQU
DIK
E3Z
EBD
EBLON
EBS
EJD
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
H13
HMCUK
HYE
HZ~
IAO
IEA
IHR
IHW
INH
INR
ITC
KQ8
M1P
M~E
NPM
O5R
O5S
O9-
OK1
P2P
P6G
PGMZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
ROL
RPM
RSV
SBL
SOJ
TR2
TUS
UKHRP
AAYXX
CITATION
ABVAZ
AFNRJ
7XB
8FK
AZQEC
DWQXO
K9.
PQEST
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c591t-27665b3ab2a7c95fdca37df60e48a46e2d08b4d524ddef2e1fde6b5b2b71c1ee3
IEDL.DBID RPM
ISSN 1758-9193
IngestDate Thu Jul 04 21:05:53 EDT 2024
Tue Sep 17 20:52:54 EDT 2024
Fri Aug 16 09:38:02 EDT 2024
Fri Sep 13 06:04:44 EDT 2024
Thu Feb 22 23:37:39 EST 2024
Fri Feb 02 04:04:14 EST 2024
Tue Aug 20 22:12:05 EDT 2024
Thu Sep 12 20:55:40 EDT 2024
Tue Aug 27 13:50:06 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Transcranial magnetic stimulation
Diagnosis
Frontotemporal dementia
Alzheimer disease
Confidence
PET amyloid
Language English
License Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c591t-27665b3ab2a7c95fdca37df60e48a46e2d08b4d524ddef2e1fde6b5b2b71c1ee3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0001-9340-9814
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145195/
PMID 30227895
PQID 2109083288
PQPubID 2040174
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_5b46b8482da445c5abfd1af1b81dfdb2
pubmedcentral_primary_oai_pubmedcentral_nih_gov_6145195
proquest_miscellaneous_2112196218
proquest_journals_2109083288
gale_infotracmisc_A557726629
gale_infotracacademiconefile_A557726629
gale_healthsolutions_A557726629
crossref_primary_10_1186_s13195_018_0423_6
pubmed_primary_30227895
PublicationCentury 2000
PublicationDate 2018-09-18
PublicationDateYYYYMMDD 2018-09-18
PublicationDate_xml – month: 09
  year: 2018
  text: 2018-09-18
  day: 18
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Alzheimer's research & therapy
PublicationTitleAlternate Alzheimers Res Ther
PublicationYear 2018
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References F Battaglia (423_CR59) 2007; 62
B Borroni (423_CR63) 2018; 62
B Borroni (423_CR14) 2007; 14
J Hardy (423_CR30) 1987; 73
M Prince (423_CR1) 2013; 9
ML Gorno-Tempini (423_CR32) 2011; 76
LM Shaw (423_CR8) 2009; 65
PJ Visser (423_CR13) 2009; 8
CM Clark (423_CR9) 2012; 11
B Borroni (423_CR45) 2015; 16
MP Lawton (423_CR43) 1969; 9
JC Morris (423_CR37) 1993; 43
GD Rabinovici (423_CR55) 2011; 77
SJ Teipel (423_CR21) 2011; 32
F Di Lorenzo (423_CR57) 2016; 80
AW Procter (423_CR29) 1999; 10
C Fraley (423_CR52) 2007; 18
AR Giovagnoli (423_CR40) 1996; 17
V Di Lazzaro (423_CR27) 2002; 59
G Koch (423_CR60) 2012; 31
AP Dempster (423_CR53) 1977; 39
P Caffarra (423_CR39) 2002; 22
A Benussi (423_CR18) 2016; 80
A Benussi (423_CR46) 2017; 36
A Padovani (423_CR16) 2018; 65
S Kumar (423_CR61) 2017; 74
P Majumder (423_CR24) 2012; 124
L Chare (423_CR34) 2014; 85
MN McDonnell (423_CR25) 2006; 173
G Novelli (423_CR38) 1986; 47
B Dubois (423_CR4) 2014; 13
GM McKhann (423_CR5) 2011; 7
G McLachlan (423_CR51) 2005
G Novelli (423_CR41) 1986; 47
G Koch (423_CR62) 2018; 169
H Tokimura (423_CR50) 2000; 523
RH Tan (423_CR28) 2017; 9
C Freitas (423_CR20) 2011; 46
E Magni (423_CR36) 1996; 3
J Levenga (423_CR23) 2013; 1
K Rascovsky (423_CR33) 2011; 134
FM Elahi (423_CR2) 2017; 13
PM Rossini (423_CR47) 2015; 126
DJ Irwin (423_CR56) 2013; 5
B Dermaut (423_CR31) 2005; 21
DC Perry (423_CR35) 2017; 140
M Boccardi (423_CR12) 2016; 73
MD Ikonomovic (423_CR11) 2008; 131
A Benussi (423_CR17) 2018; 11
AG Murley (423_CR26) 2018; 141
T Kujirai (423_CR48) 1993; 471
K Blennow (423_CR6) 2014; 39
JJ Palop (423_CR58) 2010; 13
LC de Souza (423_CR10) 2011; 82
J. L. Cummings (423_CR44) 1994; 44
KP Burnham (423_CR54) 2011; 65
A Benussi (423_CR15) 2017; 89
U Ziemann (423_CR49) 1996; 496
EJ Mufson (423_CR22) 2012; 123
GB Frisoni (423_CR3) 2017; 16
S Andrieu (423_CR7) 2015; 14
S Katz (423_CR42) 1963; 185
PT Francis (423_CR19) 1999; 66
References_xml – volume: 32
  start-page: 1349
  year: 2011
  ident: 423_CR21
  publication-title: Hum Brain Mapp
  doi: 10.1002/hbm.21111
  contributor:
    fullname: SJ Teipel
– volume: 59
  start-page: 392
  year: 2002
  ident: 423_CR27
  publication-title: Neurology
  doi: 10.1212/WNL.59.3.392
  contributor:
    fullname: V Di Lazzaro
– volume: 47
  start-page: 278
  year: 1986
  ident: 423_CR38
  publication-title: Arch Psicol Neurol Psichiatr
  contributor:
    fullname: G Novelli
– volume: 17
  start-page: 305
  year: 1996
  ident: 423_CR40
  publication-title: Ital J Neurol Sci
  doi: 10.1007/BF01997792
  contributor:
    fullname: AR Giovagnoli
– volume: 16
  start-page: 86
  year: 2015
  ident: 423_CR45
  publication-title: Amyotroph Lateral Scler Frontotemporal Degener
  doi: 10.3109/21678421.2014.971812
  contributor:
    fullname: B Borroni
– volume: 11
  start-page: 669
  year: 2012
  ident: 423_CR9
  publication-title: Lancet Neurol
  doi: 10.1016/S1474-4422(12)70142-4
  contributor:
    fullname: CM Clark
– volume: 77
  start-page: 2034
  year: 2011
  ident: 423_CR55
  publication-title: Neurology
  doi: 10.1212/WNL.0b013e31823b9c5e
  contributor:
    fullname: GD Rabinovici
– volume: 39
  start-page: 1
  year: 1977
  ident: 423_CR53
  publication-title: J R Stat Soc
  doi: 10.1111/j.2517-6161.1977.tb01600.x
  contributor:
    fullname: AP Dempster
– volume: 185
  start-page: 914
  year: 1963
  ident: 423_CR42
  publication-title: JAMA
  doi: 10.1001/jama.1963.03060120024016
  contributor:
    fullname: S Katz
– volume: 471
  start-page: 501
  year: 1993
  ident: 423_CR48
  publication-title: J Physiol
  doi: 10.1113/jphysiol.1993.sp019912
  contributor:
    fullname: T Kujirai
– volume: 9
  start-page: 63
  year: 2013
  ident: 423_CR1
  publication-title: Alzheimers Dement
  doi: 10.1016/j.jalz.2012.11.007
  contributor:
    fullname: M Prince
– volume: 13
  start-page: 614
  year: 2014
  ident: 423_CR4
  publication-title: Lancet Neurol
  doi: 10.1016/S1474-4422(14)70090-0
  contributor:
    fullname: B Dubois
– volume: 62
  start-page: 1113
  year: 2018
  ident: 423_CR63
  publication-title: J Alzheimers Dis
  doi: 10.3233/JAD-170584
  contributor:
    fullname: B Borroni
– volume: 14
  start-page: 926
  year: 2015
  ident: 423_CR7
  publication-title: Lancet Neurol
  doi: 10.1016/S1474-4422(15)00153-2
  contributor:
    fullname: S Andrieu
– volume: 80
  start-page: 472
  year: 2016
  ident: 423_CR18
  publication-title: Ann Neurol
  doi: 10.1002/ana.24731
  contributor:
    fullname: A Benussi
– volume: 134
  start-page: 2456
  year: 2011
  ident: 423_CR33
  publication-title: Brain
  doi: 10.1093/brain/awr179
  contributor:
    fullname: K Rascovsky
– volume: 126
  start-page: 1071
  year: 2015
  ident: 423_CR47
  publication-title: Clin Neurophysiol
  doi: 10.1016/j.clinph.2015.02.001
  contributor:
    fullname: PM Rossini
– volume: 13
  start-page: 457
  year: 2017
  ident: 423_CR2
  publication-title: Nat Rev Neurol
  doi: 10.1038/nrneurol.2017.96
  contributor:
    fullname: FM Elahi
– volume: 73
  start-page: 192
  year: 1987
  ident: 423_CR30
  publication-title: Neurosci Lett
  doi: 10.1016/0304-3940(87)90016-4
  contributor:
    fullname: J Hardy
– volume: 9
  start-page: 179
  year: 1969
  ident: 423_CR43
  publication-title: Gerontologist
  doi: 10.1093/geront/9.3_Part_1.179
  contributor:
    fullname: MP Lawton
– volume: 7
  start-page: 263
  year: 2011
  ident: 423_CR5
  publication-title: Alzheimers Dement
  doi: 10.1016/j.jalz.2011.03.005
  contributor:
    fullname: GM McKhann
– volume: 123
  start-page: 13
  year: 2012
  ident: 423_CR22
  publication-title: Acta Neuropathol
  doi: 10.1007/s00401-011-0884-1
  contributor:
    fullname: EJ Mufson
– volume: 8
  start-page: 619
  year: 2009
  ident: 423_CR13
  publication-title: Lancet Neurol
  doi: 10.1016/S1474-4422(09)70139-5
  contributor:
    fullname: PJ Visser
– volume: 124
  start-page: 231
  year: 2012
  ident: 423_CR24
  publication-title: Acta Neuropathol
  doi: 10.1007/s00401-012-1006-4
  contributor:
    fullname: P Majumder
– volume: 141
  start-page: 1263
  year: 2018
  ident: 423_CR26
  publication-title: Brain
  doi: 10.1093/brain/awx327
  contributor:
    fullname: AG Murley
– volume-title: Finite mixture models
  year: 2005
  ident: 423_CR51
  contributor:
    fullname: G McLachlan
– volume: 46
  start-page: 611
  year: 2011
  ident: 423_CR20
  publication-title: Exp Gerontol
  contributor:
    fullname: C Freitas
– volume: 43
  start-page: 2412
  year: 1993
  ident: 423_CR37
  publication-title: Neurology
  doi: 10.1212/WNL.43.11.2412-a
  contributor:
    fullname: JC Morris
– volume: 73
  start-page: 1417
  year: 2016
  ident: 423_CR12
  publication-title: JAMA Neurol
  doi: 10.1001/jamaneurol.2016.3751
  contributor:
    fullname: M Boccardi
– volume: 74
  start-page: 1266
  year: 2017
  ident: 423_CR61
  publication-title: JAMA Psychiatry
  doi: 10.1001/jamapsychiatry.2017.3292
  contributor:
    fullname: S Kumar
– volume: 82
  start-page: 240
  year: 2011
  ident: 423_CR10
  publication-title: J Neurol Neurosurg Psychiatry
  doi: 10.1136/jnnp.2010.207183
  contributor:
    fullname: LC de Souza
– volume: 14
  start-page: 1171
  year: 2007
  ident: 423_CR14
  publication-title: Curr Med Chem
  doi: 10.2174/092986707780598005
  contributor:
    fullname: B Borroni
– volume: 89
  start-page: 665
  year: 2017
  ident: 423_CR15
  publication-title: Neurology
  doi: 10.1212/WNL.0000000000004232
  contributor:
    fullname: A Benussi
– volume: 3
  start-page: 198
  year: 1996
  ident: 423_CR36
  publication-title: Eur J Neurol
  doi: 10.1111/j.1468-1331.1996.tb00423.x
  contributor:
    fullname: E Magni
– volume: 9
  start-page: 10
  year: 2017
  ident: 423_CR28
  publication-title: Alzheimers Dement (Amst).
  doi: 10.1016/j.dadm.2017.05.005
  contributor:
    fullname: RH Tan
– volume: 10
  start-page: 80
  year: 1999
  ident: 423_CR29
  publication-title: Dement Geriatr Cogn Disord
  doi: 10.1159/000051219
  contributor:
    fullname: AW Procter
– volume: 65
  start-page: 23
  year: 2011
  ident: 423_CR54
  publication-title: Behav Ecol Sociobiol
  doi: 10.1007/s00265-010-1029-6
  contributor:
    fullname: KP Burnham
– volume: 16
  start-page: 661
  year: 2017
  ident: 423_CR3
  publication-title: Lancet Neurol
  doi: 10.1016/S1474-4422(17)30159-X
  contributor:
    fullname: GB Frisoni
– volume: 13
  start-page: 812
  year: 2010
  ident: 423_CR58
  publication-title: Nat Neurosci
  doi: 10.1038/nn.2583
  contributor:
    fullname: JJ Palop
– volume: 1
  start-page: 34
  year: 2013
  ident: 423_CR23
  publication-title: Acta Neuropathol Commun
  doi: 10.1186/2051-5960-1-34
  contributor:
    fullname: J Levenga
– volume: 85
  start-page: 865
  year: 2014
  ident: 423_CR34
  publication-title: J Neurol Neurosurg Psychiatry.
  doi: 10.1136/jnnp-2013-306948
  contributor:
    fullname: L Chare
– volume: 65
  start-page: 403
  year: 2009
  ident: 423_CR8
  publication-title: Ann Neurol
  doi: 10.1002/ana.21610
  contributor:
    fullname: LM Shaw
– volume: 140
  start-page: 3329
  year: 2017
  ident: 423_CR35
  publication-title: Brain
  doi: 10.1093/brain/awx254
  contributor:
    fullname: DC Perry
– volume: 523
  start-page: 503
  year: 2000
  ident: 423_CR50
  publication-title: J Physiol
  doi: 10.1111/j.1469-7793.2000.t01-1-00503.x
  contributor:
    fullname: H Tokimura
– volume: 36
  start-page: 19
  year: 2017
  ident: 423_CR46
  publication-title: JIMD Rep
  doi: 10.1007/8904_2016_33
  contributor:
    fullname: A Benussi
– volume: 169
  start-page: 302
  year: 2018
  ident: 423_CR62
  publication-title: Neuroimage
  doi: 10.1016/j.neuroimage.2017.12.048
  contributor:
    fullname: G Koch
– volume: 173
  start-page: 86
  year: 2006
  ident: 423_CR25
  publication-title: Exp Brain Res
  doi: 10.1007/s00221-006-0365-2
  contributor:
    fullname: MN McDonnell
– volume: 44
  start-page: 2308
  issue: 12
  year: 1994
  ident: 423_CR44
  publication-title: Neurology
  doi: 10.1212/WNL.44.12.2308
  contributor:
    fullname: J. L. Cummings
– volume: 80
  start-page: 202
  year: 2016
  ident: 423_CR57
  publication-title: Ann Neurol
  doi: 10.1002/ana.24695
  contributor:
    fullname: F Di Lorenzo
– volume: 11
  start-page: 366
  year: 2018
  ident: 423_CR17
  publication-title: Brain Stimul
  doi: 10.1016/j.brs.2017.11.013
  contributor:
    fullname: A Benussi
– volume: 76
  start-page: 1006
  year: 2011
  ident: 423_CR32
  publication-title: Neurology
  doi: 10.1212/WNL.0b013e31821103e6
  contributor:
    fullname: ML Gorno-Tempini
– volume: 22
  start-page: 443
  year: 2002
  ident: 423_CR39
  publication-title: Neurol Sci
  doi: 10.1007/s100720200003
  contributor:
    fullname: P Caffarra
– volume: 31
  start-page: 593
  year: 2012
  ident: 423_CR60
  publication-title: J Alzheimers Dis
  doi: 10.3233/JAD-2012-120532
  contributor:
    fullname: G Koch
– volume: 47
  start-page: 477
  year: 1986
  ident: 423_CR41
  publication-title: Arch Psicol Neurol Psichiatr
  contributor:
    fullname: G Novelli
– volume: 5
  start-page: 6
  year: 2013
  ident: 423_CR56
  publication-title: Front Aging Neurosci
  doi: 10.3389/fnagi.2013.00006
  contributor:
    fullname: DJ Irwin
– volume: 21
  start-page: 664
  year: 2005
  ident: 423_CR31
  publication-title: Trends Genet
  doi: 10.1016/j.tig.2005.09.005
  contributor:
    fullname: B Dermaut
– volume: 66
  start-page: 137
  year: 1999
  ident: 423_CR19
  publication-title: J Neurol Neurosurg Psychiatry
  doi: 10.1136/jnnp.66.2.137
  contributor:
    fullname: PT Francis
– volume: 496
  start-page: 873
  year: 1996
  ident: 423_CR49
  publication-title: J Physiol
  doi: 10.1113/jphysiol.1996.sp021734
  contributor:
    fullname: U Ziemann
– volume: 39
  start-page: 189
  year: 2014
  ident: 423_CR6
  publication-title: Neuropsychopharmacology
  doi: 10.1038/npp.2013.154
  contributor:
    fullname: K Blennow
– volume: 65
  start-page: 221
  year: 2018
  ident: 423_CR16
  publication-title: J Alzheimers Dis.
  doi: 10.3233/JAD-180293
  contributor:
    fullname: A Padovani
– volume: 18
  start-page: 1
  issue: 6
  year: 2007
  ident: 423_CR52
  publication-title: J Stat Softw
  doi: 10.18637/jss.v018.i06
  contributor:
    fullname: C Fraley
– volume: 131
  start-page: 1630
  year: 2008
  ident: 423_CR11
  publication-title: Brain
  doi: 10.1093/brain/awn016
  contributor:
    fullname: MD Ikonomovic
– volume: 62
  start-page: 1405
  year: 2007
  ident: 423_CR59
  publication-title: Biol Psychiatry
  doi: 10.1016/j.biopsych.2007.02.027
  contributor:
    fullname: F Battaglia
SSID ssj0066284
Score 2.3686447
Snippet Cholinergic dysfunction is a key abnormality in Alzheimer disease (AD) that can be detected in vivo with transcranial magnetic stimulation (TMS) protocols....
Background Cholinergic dysfunction is a key abnormality in Alzheimer disease (AD) that can be detected in vivo with transcranial magnetic stimulation (TMS)...
BACKGROUNDCholinergic dysfunction is a key abnormality in Alzheimer disease (AD) that can be detected in vivo with transcranial magnetic stimulation (TMS)...
Abstract Background Cholinergic dysfunction is a key abnormality in Alzheimer disease (AD) that can be detected in vivo with transcranial magnetic stimulation...
SourceID doaj
pubmedcentral
proquest
gale
crossref
pubmed
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 94
SubjectTerms Accuracy
Alzheimer disease
Alzheimer's disease
Biomarkers
Brain research
Confidence
Dementia
Diagnosis
Frontotemporal dementia
Magnetic brain stimulation
Medical diagnosis
PET amyloid
Transcranial magnetic stimulation
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LaxsxEBYhp15CS5t027RVoBAIiKy0klZ7dEtCCKSnBHITejam9TrEzqW_vqOHjZceegksPqzGZvXNS-OdB0Jf5cBtZMqR3npFIN5wxHgRCFdetAZcqMmzCG5-yKs7fn0v7ndGfaWcsNIeuAB3LiyXVnHFvOFcOGFs9NREauGgFb0t1peKTTBVbLCUYHXrO0yq5PmKdmkmYUsVSXkgRE68UG7W_69J3vFJ03zJHQd0-Rod1JMjnpUnfoP2wvgW_QI241LpiJcRr5PncfABUoUX5ueYShQxaPGiTunCcPmSXZdWIBiOZaoono-49lhd4fTnLJ79_vMQ5ovwhOtLnHfo7vLi9vsVqfMTiBMDXRPWSylsZywzvRtE9M50vY-yDVwZLgPzrbLcC8bBxkUWaPRBWmGZ7amjIXSHaH9cjuE9wlxZD6FOCK5z3HIxxHawrDedh9_3VDbobIOnfixtMnQOL5TUBXwN4OsEvgbibwnxLWHqcJ1vAN915bv-H98b9CXxS5dy0a2e6pkQEDCAAAwNOs0USVMBfmdqwQHsKPW8mlAeTyhBw9x0eSMTumr4SrOU0QrmUKkGnWyX0zdT1toYls-JhoJDkHCKatBREaHtprs2FyGLBvUT4ZqgMl0Z5w-5_7ekuSfQh5eA8SN6xbJaDISqY7S_fnoOn-CYtbafs0b9BYIZKcI
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dixMxEA_n-eKLKH6tnhpBEITQTTbJZp-kikcR9MmDvoV83hXt9mx7L_71zmS39RZBWPqwmZZm8puZTDIfhLzVnfRZmMBaHw0DfyMwF1Vi0kRVOzChrvQi-PpNLy7kl6VanpDFIRcGwyoPOrEo6rgJeEY-ExhBCPADh815PAUI-9mH618M-0fhPevYTOMOucsF0AGy2-XR9dIatPB4p8mNnu14gz0Ka24YxoUwPbFKpXj_vyr6lo2axk_eMkjnD8j9cSdJ58PSPyQnqX9EfsCy0yHzkW4y3aMlCvABKKNrd9ljyiIFqV6PXbsoPHGItsMRcI7z0GWUrno61lzdUTyspfOfv6_Sap22dLzUeUwuzj9__7RgYz8FFlTH90y0WivfOC9cGzqVY3BNG7OukzRO6iRibbyMSkjQeVkknmPSXnnhWx54Ss0Tctpv-vSMUGl8BNcnpdAE6aXqct150bomwu9Hrivy_sBPez2UzbDF3TDaDsy3wHyLzLdA_BE5fiTEitflxWZ7aUcBsspL7Y00IjopVVDO58hd5h423Dl6UZHXuF52SB89yq2dKwUOBACgq8i7QoGSi_hxYwICzAhrYE0ozyaUIHFhOnzAhB0lfmf_4rMib47D-E2MYuvT5gZpOBgIDbuqijwdIHScdFOXpGRVkXYCrglXpiP96qrUA9e81Ah6_v-_9YLcEwXwHePmjJzutzfpJWyo9v5VkZU_APAjeA
  priority: 102
  providerName: ProQuest
Title The impact of transcranial magnetic stimulation on diagnostic confidence in patients with Alzheimer disease
URI https://www.ncbi.nlm.nih.gov/pubmed/30227895
https://www.proquest.com/docview/2109083288/abstract/
https://search.proquest.com/docview/2112196218
https://pubmed.ncbi.nlm.nih.gov/PMC6145195
https://doaj.org/article/5b46b8482da445c5abfd1af1b81dfdb2
Volume 10
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swEBdt97KXsbEvb12mwWAwUGPJkiw_pqGlDFrKWCFvQp9tWOOUJH3ZX7-TbIeavQ2MwdbZ2Lr73ens-0Doq2y4jUw5UluvCPgbjhgvAuHKi9KACTW5F8Hllby44T8WYnGAxJALk4P2nV2etPerk3Z5l2MrH1ZuOsSJTa8v55LmoijTQ3RYV9XgonfqV0pQuP3vS6rkdEur1I6wpIqkEBCSehZVZU4AFSNblEv2_6uYn1imcdTkEzN0_hK96NePeNY95yt0ENrX6DcwG3f5jngd8S7ZHwc7kC28MrdtSlTEgOVV36sLw-a7GLs0Ai5x7HqL4mWL-0qrW5w-0eLZ_Z-7sFyFDe5_5bxBN-dnv-YXpO-iQJxo6I6wWkphK2OZqV0jonemqn2UZeDKcBmYL5XlXjAOmi6yQKMP0grLbE0dDaF6i47adRveI8yV9eDwhOAqxy0XTSwby2pTebi_p7JA34f51A9dsQydnQwldccHDXzQiQ8aiE_TjO8JU53rfGK9udU9t7WwXFrFFfOGc-GEsdFTE6mFZXb0lhXoc-KX7pJG92jVMyHAbQBZaAr0LVMkvML0O9OnHcAbpcpXI8rjESXgzI2HB5nQPc63mqW4VlCKShXoy344XZli19qwfkw0FMyChLVUgd51IrR_6UESC1SPhGs0K-MRAEWuAt6D4MN_X_kRPWcZFg2h6hgd7TaP4ROssHZ2Arha1BP07PTs6vonHM3lfJK_Vkwy1v4Cg-EtDg
link.rule.ids 230,315,733,786,790,870,891,2115,12083,21416,27957,27958,31754,31755,33779,33780,43345,43840,53827,53829
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1NaxQxNGg96EUUv8ZWG0EQhNBJJslkTrKKZdW2pxb2FvLZLrqz7e724q_3JZNdOwjCMIfJm2Hy8j6T94HQe9lxG5lypLVeEfA3HDFeBMKVF7UBFWpyL4LTMzm94N9nYlY23NYlrHIrE7Og9kuX9siPWIogBPJT6tP1DUldo9LpammhcR894E3DU0hfO9s5XFKC7C0nmVTJozVtUmfCmiqSokGIHOmiXLL_X8F8RzONoybvqKHjJ-hxsR_xZFjwp-he6J-hn7DYeMh3xMuIN0n_OLgBbeGFuexToiIGXl6UXl0YLj_E2KURcInj0FsUz3tcKq2ucdqixZNfv6_CfBFWuBzlPEcXx1_Pv0xJ6aJAnOjohrBWSmEbY5lpXSeid6ZpfZR14MpwGZivleVeMA6SLrJAow_SCstsSx0NoXmB9vplH14hzJX14PCE4BrHLRddrDvLWtN4-L6nskIft_jU10OxDJ2dDCX1gHwNyNcJ-RqAPyeM7wBTnev8YLm61IVttLBcWsUV84Zz4YSx0VMTqQUzO3rLKnSY1ksPSaM7btUTIcBtAALoKvQhQyR-BfQ7U9IOYEap8tUI8mAECXzmxsNbmtCFz9f6L1VW6N1uOL2ZYtf6sLxNMBTUggRbqkIvBxLaTbqpcyqyqFA7Iq4RVsYj_fwqVwGXNFcGev3_3zpED6fnpyf65NvZj330iGXi7whVB2hvs7oNb8Ck2ti3mW_-ADMiIqs
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swEBdbB2Mv-2Bf3rpVg8Fg4MSSJVl-zLqF7qOlDyuUvQh9tqGNE5rkpX_9TrId4u2tEPwQnQ3S_XSns393h9BHUTMTqLR5ZZzMId6wuXbc50w6XmhwoTr1Ijg-EUdn7Mc5P99p9ZVI-9bMRs31fNTMLhO3cjm3454nNj49PhQkFUUZL10Y30cPYM_Sug_UWyMsBJjd7iMmkWK8ImVsSlgQmUciSB47F5VFSgPlA4-UCvf_b553_NOQO7njjKZP0J9-Gi0H5Wq0WZuRvf2nwuOd5vkUPe6OqHjSijxD93zzHF0BnnCbUokXAa-ji7NwAfjiub5oYi4kBnMx79qBYfi5lsYXRyDqDm37UjxrcFfMdYXjW2A8ub699LO5v8Hd16IX6Gz67ffhUd41asgtr8k6p5UQ3JTaUF3ZmgdndVm5IArPpGbCU1dIwxynDIxpoJ4E54XhhpqKWOJ9-RLtNYvGv0aYSeMgpvLelpYZxutQ1IZWunTwfEdEhj73ylLLth6HSnGMFKpVsgIlq6hkBcJfojq3grGUdvpjcXOhuoVW3DBhJJPUaca45doER3QgBk7ywRmaoYMIBtXmpW4NgppwDpEJAK3O0KckEU0CLL_VXWYDzCgW1xpI7g8kYSvb4XAPONWZkpWikToLdlfKDH3YDsc7Iz2u8YtNlCHgeQQc1zL0qsXndtI9zDNUDZA7WJXhCOAxFRrv8PfmznceoIenX6fq1_eTn2_RI5q2X50TuY_21jcb_w7Oc2vzPu3cvzqHTTI
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+impact+of+transcranial+magnetic+stimulation+on+diagnostic+confidence+in+patients+with+Alzheimer+disease&rft.jtitle=Alzheimer%27s+research+%26+therapy&rft.au=Benussi%2C+Alberto&rft.au=Alberici%2C+Antonella&rft.au=Ferrari%2C+Clarissa&rft.au=Cantoni%2C+Valentina&rft.date=2018-09-18&rft.pub=BioMed+Central&rft.eissn=1758-9193&rft.volume=10&rft_id=info:doi/10.1186%2Fs13195-018-0423-6&rft_id=info%3Apmid%2F30227895&rft.externalDBID=PMC6145195
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1758-9193&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1758-9193&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1758-9193&client=summon